REVB (Revelation Biosciences) Common Stock : $0.00 Mil (As of Dec. 2024)

View and export this data going back to 2022. Start your Free Trial

What is Revelation Biosciences Common Stock?

Revelation Biosciences's quarterly common stock increased from Jun. 2024 ($0.00 Mil) to Sep. 2024 ($0.00 Mil) but then declined from Sep. 2024 ($0.00 Mil) to Dec. 2024 ($0.00 Mil).

Revelation Biosciences's annual common stock stayed the same from Dec. 2022 ($0.00 Mil) to Dec. 2023 ($0.00 Mil) but then increased from Dec. 2023 ($0.00 Mil) to Dec. 2024 ($0.00 Mil).

Revelation Biosciences Common Stock Historical Data

The historical data trend for Revelation Biosciences's Common Stock can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Revelation Biosciences Common Stock Chart

Revelation Biosciences Annual Data

Trend

Dec20

Dec21

Dec22

Dec23

Dec24

Common Stock

Revelation Biosciences Quarterly Data
	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
Common Stock	Get a 7-Day Free Trial												-	-	-	-	-

Revelation Biosciences Common Stock Calculation

Common stock is listed on the Balance Sheet at the par value of the total shares outstanding of a company.

The par value of common stocks is meaningless. It is usually set at an absurdly low number.

Revelation Biosciences Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Revelation Biosciences Inc (NAS:REVB) » Definitions » Common Stock

Comparable Companies

Traded in Other Exchanges

N/A

Address

4660 La Jolla Village Drive, Suite 100, San Diego, CA, USA, 92122

Website

https://www.revbiosciences.com

Revelation Biosciences Inc is a clinical-stage life science company that is focused on rebalancing inflammation to optimize health using its proprietary formulation Gemini. It is developing a pipeline of potential high-value products based on Gemini. Gemini is Revelation's proprietary formulation of phosphorylated hexaacyl disaccharide (PHAD) an established TLR4 agonist that can stimulate the human body's innate immune response to prevent and treat disease. The product candidates are developed are based on Gemini formulation of PHAD. Gemini-based programs consist of: Gemini-SSI developed for the prevention of surgical site infection (SSI); Gemini-AKI developed for the prevention of acute kidney injury (AKI); and Gemini-CKD for the treatment of chronic kidney disease (CKD).

Executives

George F Tidmarsh	director, 10 percent owner
Lakhmir S Chawla	director	1960 KIRBY ROAD, MCLEAN VA 22101
Axa Im Prime Impact Gp S.a.r.l	other: Former 10% owner	2-4, RUE EUGENE RUPPERT, LUXEMBOURG N4 L-2453
Axa Im Prime Impact Master Fund I Sca Sicav-raif	other: Former 10% Owner	2-4 RUE EUGENE RUPPERT, LUXEMBOURG N4 L-2453
Axa Investment Managers S.a.	other: Former 10% owner	6 PLACE DE LA PYRAMIDE, TOUR MAJUNGA, PUTEAUX I0 92800
Axa Investment Managers Paris	other: Former 10% owner	6 PLACE DE LA PYRAMIDE, PUTEAUX I0 92800
Axa Investment Managers Uk Ltd	other: Former 10% owner	22 BISHOPGATE, LONDON X0 EC2M 3XJ
S.a. Axa	other: Former 10% owner	25 AVENUE MATIGNON, PARIS I0 75008
Jess Roper	director	5555 OBERLIN DRIVE, SAN DIEGO CA 92121
James Rolke	director, officer: Chief Executive Officer	10182 TELESIS COURT, 6TH FLOOR, SAN DIEGO CA 92121
Curt H Labelle	director	C/O INVESTOR GROWTH CAPITAL, INC., 630 FIFTH AVENUE, SUITE 1965, NEW YORK NY 10011
Jennifer Carver	director	725 NEWPORT STREET, DENVER CO 80220
Zygmont Chester Stanley Iii	officer: Chief Financial Officer	3322 MILLIKIN AVE, SAN DIEGO CA 92122
Lawrence Feis	10 percent owner	190 EAST WALTON PLACE, UNIT 603, CHICAGO IL 60611
Feis Equities Llc	10 percent owner	20 NORTH WACKER DRIVE, SUITE 2115, CHICAGO IL 60606